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ABBREVIATIONS






SHIP-1, an inositol 5-phosphatase expressed in hemopoietic cells, acts by hydrolysing the 5-phosphates from phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) and inositol-1,3,4,5-tetrakisphosphate (InsP4), thereby negatively regulating the PI3K pathway.  SHIP-1 plays a major role in inhibiting proliferation of myeloid cells.  As a result, SHIP-1-/- mice have an increased number 

of neutrophils and monocytes/macrophages 
due to enhanced survival and proliferation of their progenitors.  Although SHIP-1 contributes to PtdIns(3,4,5)P3 metabolism in T lymphocytes, its exact role in this cell type is much less explored.  Jurkat cells have recently emerged as an interesting tool to study SHIP-1 function in T cells because they do not express SHIP-1 at the protein level, thereby allowing reintroduction experiments in a relatively easy to use system.  Data obtained from SHIP-1 reintroduction have revealed that SHIP-1 not only acts as a negative player in T cell lines proliferation, but also regulate critical pathways, such as NF-κB activation, and also appear to remarkably inhibit T cell apoptosis.  On the other hand, experiments using primary T cells from SHIP-1-/- mice have highlighted a new role for SHIP-1 in regulatory T cell development, but also emphasize that this protein is not required for T cell proliferation.  In support of these results, SHIP-1-/- mice are lymphopenic, suggesting that SHIP-1 function in T cells differs from its role in the myeloid lineage.  

INTRODUCTION
The PI3K pathway regulates many important cellular functions, such as survival, proliferation, cell activation and migration [1-3].  Upon activation, PI3K generates phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2.  PtdIns(3,4,5)P3 attracts pleckstrin homology (PH) domain-containing proteins to the plasma membrane, which allows their activation and subsequent signalling.  PH domain-containing proteins include notably Akt, a key messenger in cellular proliferation and protection from apoptosis [4].  The negative regulation of the PI3K pathway is achieved notably by PTEN (phosphatase and tensin homologue deleted on chromosome 10), which hydrolyses PtdIns(3,4,5)P3 back to PtdIns(4,5)P2 [5], and by SH2-containing inositol-5-phosphatase-1 (SHIP-1), which hydrolyses the 5-phosphates from phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) and inositol-1,3,4,5-tetrakisphosphate (InsP4) [6]. SHIP-1, a 145 kDa protein expressed in hemopoietic cells, contains a central phosphatase domain, an N-terminal SH2 domain and a C-terminal domain containing phosphorylable NPXY sites and proline-rich sequences (Figure 1) [7].  SH2 domain and NPXY sites mediate the binding of SHIP-1 with a series of consensus motifs or adapter proteins, like immunoreceptor signalling motifs (ITIM and ITAM) and various Doks [8, 9].  Through its inositol phosphatase activity, SHIP-1 influences PtdIns(3,4,5)P3 levels in many cell types, which has a crucial impact in the negative regulation of cellular proliferation and apoptosis. In support of this, SHIP-1-/- mice have an increased number of myeloid cells due to enhanced survival and proliferation of their progenitors, thereby resulting in splenomegaly and myeloid infiltration in various organs, including lungs [10, 11].  SHIP-1-/- myeloid cells exhibit furthermore decreased susceptibility to apoptotic cell death, an observation that has to be linked to the constitutive Akt activation in these cells, leading to enhanced survival and proliferation [11].  This observation is reinforced by the demonstration that a dominant-negative mutation reducing catalytic activity of SHIP-1 was found to be associated with acute myeloid leukaemia [12].     
SHIP-1 also acts at different levels in B cell biology.  SHIP-1-/- mice exhibit a reduction in the number of pre-B and immature B cells in the bone marrow, but increased number of hypermature B cells in the spleen.  B cells from SHIP-1-/- mice are also hypersensitive to BCR stimulation, but less sensitive to apoptosis [10, 13-16].  These data reflect that the inhibitory signals mediated by SHIP-1 have positive or negative impacts depending on the stage of B cell development.  The molecular mechanisms underlying SHIP-1-mediated inhibition of B cell proliferation are now well understood.  Signalling pathways induced by BCR activation are inhibited by co-aggregation between BCR and FcγRIIB, a low affinity Fc receptor.  This co-aggregation occurs when IgG-containing immune complexes bind simultaneously the BCR and FcγRIIB and trigger tyrosine phosphorylation within immunoreceptor tyrosine-based inhibitory motifs (ITIM) of the cytoplasmic tail of FcγRIIB [17].  This phosphorylation induces the recruitment of SHIP-1 to the tyrosine phosphorylated ITIM of FcγRIIB via its SH2 domain.  SHIP-1 then dephosphorylates PtdIns(3,4,5)P3, leading to inhibition of PLCγ, Akt and Btk, thereby inhibiting proliferation and calcium mobilisation ([18-20] and [13] for review).  SHIP-1 also functions in FcγRIIB-mediated inhibitory signals upon FcεR1-induced degranulation in mast cells ([21-23] and [9] for review).

ROLE OF SHIP-1 IN T LYMPHOCYTES

Data obtained from T cell lines
Although the role of SHIP-1 has been intensely studied in myeloid and B cells, its exact biological function in T cells remains poorly understood.  Pioneer works have demonstrated a tyrosine phosphorylation of SHIP-1 upon CD3 and CD28 stimulation, and redistribution of its catalytic activity at the plasma membrane [24, 25], without highlighting a clear biological role of SHIP-1 in the regulation of T cell activation.  SHIP-1 was also reported to interact with the ξ chain of the TCR, at least in vitro [26].  An embryonic work has also demonstrated that FcγRIIB co-aggregation with the TCR results in tyrosine phosphorylation of SHIP-1, indicating that, like in B cells, SHIP-1 would be responsible for FcγRIIB-elicited inhibitory signalling in T cells [27].  Finally, SHIP-1 was demonstrated to play a role in LFA-1-dependent adhesion [28].     
The finding that the Jurkat T cell line was defective in SHIP-1 (and PTEN) expression [29-31] has opened up new possibilities for studying SHIP-1 biological role in T cells by complementation experiments.  Because of their deficiency in SHIP-1 expression, Jurkat cells express a very high level of  PtdIns(3,4,5)P3 and a subsequent constitutive Akt activation compared to other leukemic cell lines (such as CEM, MOLT-4 or HUT78) or human PBLs [32].  Restoration of SHIP-1 activity in Jurkat cells was first carried out using a Tet-Off regulated system encoding the lipid phosphatase core of SHIP-1 fused to the transmembrane region of rat CD2.  Expression of this membrane-localized SHIP-1 in Jurkat was sufficient to reduce Akt constitutive activation and the activity of downstream PI3K effector, constituting the first evidence that SHIP-1 is capable of modulating important signalling pathways in T cells [32].  Ectopic expression of the complete SHIP-1 protein was also achieved in Jurkat cells by Horn et al.  SHIP-1 expressing Jurkat cells have reduced PtdIns(3,4,5)P3 level compared to the parental clone, and subsequent diminution of Akt phosphorylation on S473 and T308.  Phosphorylation of GSK-3β, an Akt substrate, is also down regulated upon SHIP-1 reexpression [33].  Interestingly, expression of SHIP-1 in Jurkat also reduces cellular proliferation, notably by affecting the G1 cell cycle regulators Rb and p27Kip1 [33] and KLF2, a factor implicated in T cell quiescence [34].  Altogether, these reintroduction experiments have highlighted a role for SHIP-1 in negatively regulating T cell lines proliferation.  In support of this, down-regulation of SHIP-1 expression has been described in adult T cell leukaemia (ATLL) [35].  





Cell type	Apoptosis inducer	Role of SHIP-1	References
Myeloid cells 	Sorbitol, cycloheximide, anisomycin A, anti-Fas antibody, TNF-α	Pro-apoptotic	[11, 40]
Erythroid cells	EPO deprivation	Pro-apoptotic	[39]
B cells	Aggregation of the BCR	Pro-apoptotic	[14]
	Activin/TGF-β	Pro-apoptotic	[41]
	Clustering of FcγRIIB independently of BCR coligation	Anti-apoptotic	[42]
T cells	H2O2	Anti-apoptotic	[38]

Table I: Pro- or anti-apoptotic role of SHIP-1 in different hemopoietic cells and biological conditions.


Data obtained from primary T cells
As described above, generation of SHIP-1 deficient mice have considerably increased our understanding of its biological role.  These mice have notably revealed that SHIP-1 does not function similarly in the lymphoid than in the myeloid lineage. Indeed, whereas SHIP-1 KO mice have more myeloid cells than wt mice, they exhibit a reduction in the T cell population [10, 11].  An elegant study carried out by the Rothman’s group recently addressed SHIP-1’s role in primary mouse T cells [44].  These authors have demonstrated that, like in B cells, SHIP-1 appears to play a biphasic role in T 

cell physiology.  First, SHIP-1, together with the adapter protein Dok-1, plays a key role in T cell development, since mice deficient for both SHIP-1 and Dok-1 exhibit an important reduction in the percentage of CD4+ and CD8+ double positive, together with an increased number of CD4- and CD8- double negative cells [44].  On the other hand, there is a reduced number of T cells in the spleen from SHIP-1 KO mice, due to a severe reduction of CD8+ T cells, suggesting that SHIP-1 is important in maintaining CD4+/CD8+ ratio in the periphery.  But the most intriguing feature of CD4+ T cells from SHIP-1 KO mice is that they are phenotypically and functionally regulatory T cells (Tregs) [44].  Indeed, splenic T cells from SHIP-1 KO mice are activated, but do not respond to TCR stimulation or produce cytokines in response to PMA stimulation.  They exhibit furthermore Tregs markers (such as high TGFβ production and expression of the transcription factor Foxp3) and are able to suppress IL-2 production by CD4+ CD25- T cells upon CD3 stimulation.  T cells from mice deficient for both SHIP-1 and Dok-1 share the same phenotype, highlighting the crucial role of the adaptor Dok-1 for SHIP-1 activity [44].  An analogous cooperation of Dok-1 with SHIP-1 has already been demonstrated in FcγRIIB signalling in B cells, where SHIP-1 serves as an adaptor protein to recruit Dok-1 to the receptor, which in turn, inhibits the Ras/MAPK pathway [45].
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Figure 1.  A.  Structure of the SHIP-1 protein.  B.  Through its lipid phosphatase activity, SHIP-1 dephosphorylates PtdIns(3,4,5)P3 to PtdIns(3,4,)P2, thereby negatively regulating the PI3K pathway.  PTEN exerts the same function, but catalyzes PtdIns(3,4,5)P3 back into PtdIns(4,5)P2.  See text for details.  
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